Otsuka Pharmaceutical: cross-border access for the specialty portfolio

Quick orientation

Otsuka Pharmaceutical Co., Ltd. is a Japanese global healthcare company headquartered in Tokyo, with US operations in Princeton, New Jersey. Otsuka is a top-25 global pharma with deep franchises in central nervous system disorders, oncology, nephrology, and infectious disease, and is the co-developer of Abilify (with Bristol Myers Squibb) and the developer of Rexulti. The company also operates Otsuka America Pharmaceutical, Inc. and a separate consumer-health division. Otsuka trades on the Tokyo Stock Exchange. FDA approval scale spans approximately a dozen marketed products across CNS, oncology, and rare-disease indications, including the newer franchises in autosomal dominant polycystic kidney disease and Rett syndrome (with development partner Acadia).

Otsuka portfolio in cross-border NPP scope

Daybue (trofinetide), developed by Acadia Pharmaceuticals and commercialised through strategic relationships that include Otsuka in select Asian markets, is an FDA-approved oral solution for the treatment of Rett syndrome in adult and pediatric patients two years of age and older (FDA approval March 2023). Daybue is the first FDA-approved treatment for Rett syndrome. US list pricing is approximately US$21,500 per month for an average patient. The product is a weight-based oral solution administered twice daily.

Rexulti (brexpiprazole) is an FDA-approved atypical antipsychotic for schizophrenia and adjunctive treatment of major depressive disorder, with a 2023 expanded indication for agitation associated with Alzheimer's dementia - the first FDA-approved therapy for this indication. Oral dosing. The Alzheimer's agitation indication, supported by two Phase 3 trials, made Rexulti the first option with US labeled use for behavioral symptoms of dementia.

Abilify (aripiprazole) is now genericised in most jurisdictions, but the branded long-acting injectables Abilify Maintena and Abilify Asimtufii remain commercial Otsuka products and are not generically available.

Jynarque (tolvaptan) is FDA-approved to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Samsca (tolvaptan) for hyponatremia is the same active ingredient at different dosing and labeling.

Pretomanid for highly drug-resistant tuberculosis is an Otsuka-affiliated TB Alliance product used in combination regimens.

Why patients route through cross-border NPP

Daybue is the highest-volume cross-border NPP demand driver in the Otsuka/Acadia portfolio. Rett syndrome is an X-linked neurodevelopmental disorder affecting approximately one in 10,000 to 15,000 live female births, and Daybue is the first and only FDA-approved disease-modifying therapy. Outside the United States, regulatory adoption has been slow: as of mid-2026 the product is approved in Canada and has filings underway in Europe, but has not yet launched in the GCC, India, or most of MENA. Families of children with genetically confirmed MECP2 mutations routinely seek cross-border NPP supply for the only available targeted therapy. The condition is severe and progressive, and the diagnostic pathway typically takes years to confirm - by the time families reach Reserve Meds, the genetic confirmation is well established but treatment options locally are nonexistent.

Rexulti for Alzheimer's agitation is a separate cross-border demand driver. Behavioral and psychiatric symptoms of dementia are a major caregiver burden globally, and Rexulti is the first FDA-approved option specifically labeled for this indication. Off-label antipsychotic use carries known cardiovascular and mortality risks in the elderly, and families seek the FDA-labeled product where reimbursement is unavailable locally.

Jynarque for ADPKD addresses an additional rare-disease need where local options are limited. ADPKD is the most common monogenic kidney disease worldwide, and Jynarque is one of few therapies that demonstrably slows progression.

Common cross-border destinations

The highest-frequency NPP destinations for Otsuka products from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey. Pediatric neurology centers for Daybue, psychiatry centers for Rexulti, and nephrology centers for Jynarque drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Otsuka-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Otsuka Pharmaceutical. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription. For Otsuka medical affairs or US commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Otsuka product request, Reserve Meds coordinates: prescription verification with the treating physician; genetic confirmation documentation review where indicated (MECP2 mutation for Daybue, PKD1/PKD2 for Jynarque where required for protocol); DSCSA serialized chain-of-custody from Otsuka through licensed US wholesalers to the named patient; ambient or refrigerated shipping per product specification; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients or caregivers with a treating-physician prescription for an Otsuka product can begin a request now. Start a Daybue request ›

Next step for Otsuka teams

Otsuka medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.